Search

Displaying results 6891 - 6900 of 8195 in total
  1. Drug

    Linaprazan

    go.drugbank.com/drugs/DB20602
    Investigational

    Linaprazan has a monoisotopic molecular weight of 366.21 Da.

  2. Drug

    Prusogliptin

    go.drugbank.com/drugs/DB20606
    Investigational

    Prusogliptin has a monoisotopic molecular weight of 324.2 Da.

  3. Drug

    Guretolimod

    go.drugbank.com/drugs/DB21487
    Investigational

    Guretolimod has a monoisotopic molecular weight of 513.26 Da.

  4. Drug

    Ocedurenone

    go.drugbank.com/drugs/DB21519
    Investigational

    Ocedurenone has a monoisotopic molecular weight of 503.21 Da.

  5. Drug

    Selnoflast

    go.drugbank.com/drugs/DB21522
    Investigational

    Selnoflast has a monoisotopic molecular weight of 391.19 Da.

  6. Drug

    Brimarafenib

    go.drugbank.com/drugs/DB21706
    Investigational

    Brimarafenib has a monoisotopic molecular weight of 482.12 Da.

  7. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation,

  8. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    If this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD.

  9. Drug

    Inositol 1,3-bisphosphate

    go.drugbank.com/drugs/DB02942
    Experimental

    The compound corresponds to the soluble headgroup of phosphatidylinositol 3-phosphate (PtdIns(3)P), an endosomal signaling lipid recognized by FYVE domains, and it has been used as a ligand in structural … It is an experimental compound with no approved therapeutic indications.

  10. Drug

    AV608

    go.drugbank.com/drugs/DB05072
    Investigational

    AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).